CN110114066B - 含沙丁胺醇的眼科药物 - Google Patents

含沙丁胺醇的眼科药物 Download PDF

Info

Publication number
CN110114066B
CN110114066B CN201780052188.6A CN201780052188A CN110114066B CN 110114066 B CN110114066 B CN 110114066B CN 201780052188 A CN201780052188 A CN 201780052188A CN 110114066 B CN110114066 B CN 110114066B
Authority
CN
China
Prior art keywords
composition
administered
eye
concentration
leucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780052188.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110114066A (zh
Inventor
拉乌夫·雷基克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN110114066A publication Critical patent/CN110114066A/zh
Application granted granted Critical
Publication of CN110114066B publication Critical patent/CN110114066B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780052188.6A 2016-06-27 2017-06-27 含沙丁胺醇的眼科药物 Active CN110114066B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TNTN2016/0259 2016-06-27
TN2016000259A TN2016000259A1 (en) 2016-06-27 2016-06-27 Salbutamol (albuterol) eye protective medicament.
PCT/IB2017/000779 WO2018007864A1 (en) 2016-06-27 2017-06-27 Salbutamol-containing ophthalmic medicament

Publications (2)

Publication Number Publication Date
CN110114066A CN110114066A (zh) 2019-08-09
CN110114066B true CN110114066B (zh) 2023-06-27

Family

ID=59416735

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780052188.6A Active CN110114066B (zh) 2016-06-27 2017-06-27 含沙丁胺醇的眼科药物

Country Status (7)

Country Link
US (1) US11484513B2 (cg-RX-API-DMAC7.html)
EP (1) EP3474836B1 (cg-RX-API-DMAC7.html)
JP (1) JP7176960B2 (cg-RX-API-DMAC7.html)
CN (1) CN110114066B (cg-RX-API-DMAC7.html)
MA (1) MA45457A (cg-RX-API-DMAC7.html)
TN (1) TN2016000259A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018007864A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119097618A (zh) * 2019-03-02 2024-12-10 内在生物技术有限公司 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物
KR20220018484A (ko) * 2019-06-10 2022-02-15 제니비젼 인크. 시력 장애를 치료하기 위한 방법 및 제형
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
JP7066293B2 (ja) * 2019-11-12 2022-05-13 株式会社ファンケル サーチュイン1(sirt1)発現増強用組成物
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
KR20230015433A (ko) * 2020-05-22 2023-01-31 인트라바이오 리미티드 운동실조를 치료하기 위한 아세틸 류신과 4-아미노피리딘 또는 아세타졸아미드의 조합물
EP4694929A1 (en) * 2023-04-08 2026-02-18 Sung-Jan Lin Methods for treating corneal injuries

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985897A (en) * 1973-12-21 1976-10-12 Mead Johnson & Company Ocular hypotensive process employing dextrorotatory sulfonamidophenethanolamines
SE8701258D0 (sv) * 1987-03-26 1987-03-26 Pharmacia Ab A composition for the topical treatment of glaucoma or ocular hypertension
US5192780A (en) * 1989-12-18 1993-03-09 Alcon Laboratories, Inc. Methods using antiallergics and antihistamines
US6569903B2 (en) * 1999-12-07 2003-05-27 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
WO2003049745A1 (en) 2001-12-12 2003-06-19 Pharmacia Corporation Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
EP2311793A1 (en) 2004-12-17 2011-04-20 Cipla Ltd. Crystalline levosalbutamol sulphate (Form II)
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
WO2011068786A2 (en) * 2009-12-02 2011-06-09 Bridge Pharma, Inc. Treating xerophthalmia with compounds increasing meibomian gland secretion
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
WO2014191414A1 (en) * 2013-05-28 2014-12-04 Sanovel Ilac Sanayi Ve Ticaret A.S. Syrup formulation of salbutamol

Also Published As

Publication number Publication date
MA45457A (fr) 2019-05-01
CN110114066A (zh) 2019-08-09
EP3474836C0 (en) 2024-01-17
CA3028924A1 (en) 2018-01-11
US20190160027A1 (en) 2019-05-30
WO2018007864A1 (en) 2018-01-11
TN2016000259A1 (en) 2017-10-06
JP2019524679A (ja) 2019-09-05
RU2018146575A3 (cg-RX-API-DMAC7.html) 2020-09-24
US11484513B2 (en) 2022-11-01
EP3474836A1 (en) 2019-05-01
EP3474836B1 (en) 2024-01-17
JP7176960B2 (ja) 2022-11-22
RU2018146575A (ru) 2020-07-28

Similar Documents

Publication Publication Date Title
Lee et al. Glaucoma and its treatment: a review
JP7176960B2 (ja) サルブタモール含有眼科用医薬
CA2718161C (en) Drug delivery to the anterior and posterior segments of the eye using eye drops
Benozzi et al. Presbyopia treatment with eye drops: an eight year retrospective study
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
JP2013544275A (ja) 葉酸−ラミプリルの組合せ:細胞保護性、神経保護性、および網膜保護性の眼科用組成物
JP2005501100A (ja) 視力を改善する生理学的方法
Schellack et al. Glaucoma: a brief review
Gonzalez-Salinas et al. Patient considerations in cataract surgery–the role of combined therapy using phenylephrine and ketorolac
Wood et al. Rare corneal complication following selective laser trabeculoplasty
Yanoff Ophthalmic diagnosis & treatment
Tsujinaka et al. A case of bilateral deep stromal corneal opacity and vascularization after use of multiple antiglaucoma medications including brimonidine tartrate ophthalmic solution.
Marais et al. The medical management of glaucoma
RU2774971C2 (ru) Офтальмологическое лекарственное средство, содержащее сальбутамол
CA3028924C (en) Salbutamol-containing ophthalmic medicament
Stradiotto et al. Glaucoma pharmacology
Kartasasmita et al. The effectiveness of continuous intravitreal adrenaline as mydriatic adjuvant on pars plana vitrectomy in diabetic patient, a randomized clinical trial
Berco et al. Management of Diabetic Retinopathy and Other Ocular Complications in Type 1 Diabetes
Mentes et al. Do mydriatics effect serous pigment epithelial detachment elevation? A case report on central serous chorioretinopathy
Barton et al. Sharing best practice and landmark evidence in glaucoma care
Song et al. Success in The Duke Elder Examination: 180 MCQs
Dada et al. Medical Management of Glaucoma
TR2023018016A2 (tr) Kornea hastaliklari i̇laç tedavi̇si̇ndekullanilmak üzere geli̇şti̇ri̇len kompozi̇syon
Ramlal Interventional Follow Up Study of Resolution of Macular Edema After Intravitreal Triamcinolone Injection in Pseudophakic Patients with Macular Edema More than 350 Micron
Schellack et al. Glaucoma: a brief update for 2017

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant